Tagatose, a new antidiabetic and obesity control drug

背景(考古学) 医学 2型糖尿病 糖尿病 药品 果糖 餐后 药理学 内分泌学 化学 生物 食品科学 古生物学
作者
Yuan Lu,G. V. Levin,Thomas W. Donner
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:10 (2): 109-134 被引量:255
标识
DOI:10.1111/j.1463-1326.2007.00799.x
摘要

A potentially important new drug for treating type 2 diabetes, tagatose, is now in phase 3 clinical trial. The history, development, additional health benefits, mechanisms of action and the potential for the drug are presented in context with a review of the rapidly growing epidemic of type 2 diabetes and treatments for it. An epimer of fructose, the natural hexose tagatose was originally developed by Spherix Incorporated (formerly Biospherics Inc.) as a low-calorie sugar substitute. Only 20% of orally ingested tagatose is fully metabolized, principally in the liver, following a metabolic pathway identical to that of fructose. Following a decade of studies, tagatose became generally recognized as safe for use in foods and beverages under US FDA regulation. The simple sugar is commercially produced by isomerization of galactose, which is prepared from lactose. Early human studies suggested tagatose as a potential antidiabetic drug through its beneficial effects on postprandial hyperglycaemia and hyperinsulinaemia. A subsequent 14-month trial confirmed its potential for treating type 2 diabetes, and tagatose showed promise for inducing weight loss and raising high-density lipoprotein cholesterol, both important to the control of diabetes and constituting benefits independent of the disease. Furthermore, tagatose was shown to be an antioxidant and a prebiotic, both properties cited in the maintenance and promotion of health. No current therapies for type 2 diabetes provide these multiple health benefits. The predominant side effects of tagatose are gastrointestinal disturbances associated with excessive consumption, generally accommodated within 1- to 2-week period. The health and use potentials for tagatose (branded Naturlose((R)) for this use) are given with respect to current type 2 diabetes drugs and markets. Under an FDA-affirmed protocol, Spherix is currently conducting a phase 3 trial to evaluate a placebo-subtracted treatment effect based on a decrease in HbA(1c) levels. Side effects, contraindications and possibly beneficial new findings will be carefully monitored. It is hoped that early results of the trial may become available by mid-2008. If a subsequent NDA is successful, tagatose may fill a major health need.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我是老大的应助被面包树不圆采纳,获得10
刚刚
冷傲的不愁完成签到,获得积分10
1秒前
1秒前
Hello的应助被何大爷采纳,获得10
1秒前
1秒前
2秒前
完美世界的应助被corleeang采纳,获得10
2秒前
李爱国的应助被繁荣的向日葵采纳,获得10
2秒前
2秒前
ppp关闭了ppp的文献求助
4秒前
三水完成签到,获得积分10
4秒前
DW的应助被花火采纳,获得10
4秒前
5秒前
充电宝的应助被纹纹采纳,获得20
5秒前
喷火娃的应助被诺贝尔候选人采纳,获得10
5秒前
迷路哑铃完成签到,获得积分10
6秒前
今后的应助被曾经的安珊采纳,获得10
6秒前
6秒前
王思甜完成签到,获得积分20
6秒前
如意的醉蓝完成签到,获得积分10
6秒前
6秒前
7秒前
酷波er的应助被健忘星月采纳,获得10
8秒前
三水发布了新的文献求助10
8秒前
ZZX完成签到,获得积分10
8秒前
8秒前
内向从灵完成签到 ,获得积分10
9秒前
ssu发布了新的文献求助20
9秒前
搜集达人的应助被corleeang采纳,获得10
9秒前
大模型的应助被居里夫人采纳,获得10
9秒前
9秒前
9秒前
9秒前
10秒前
11秒前
犹豫颖完成签到,获得积分10
11秒前
Hello的应助被qin202569采纳,获得10
11秒前
北风北风完成签到,获得积分10
11秒前
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124